# 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

> **NCT00558571** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 78 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 10773 low dose
- **DRUG:** placebo to BI 10773
- **DRUG:** BI 10773 medium dose
- **DRUG:** BI 10773 high dose

## Key facts

- **NCT ID:** NCT00558571
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558571, "4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00558571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*